Organon & Co. announced results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream in children aged 2-17 with atopic dermatitis. The findings, which will be presented at the 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting on November 8, 2025, indicate that VTAMA cream provided early and consistent improvements in skin clearance, severity, patient-reported outcomes, and itch, regardless of the presence of atopic comorbidities such as asthma, allergic rhinitis, and food allergies. Clinically meaningful improvements in itch were observed as early as week 2, with continued improvement through week 8. The most frequently reported treatment-emergent adverse events included folliculitis (7.8%), upper respiratory tract infection (4.6%), and headache (3.7%).